According to Pulmatrix, the Cystic Fibrosis Foundation Therapeutics (CFFT) will provide funds to support non-clinical development of PUR1900, an itraconazole DPI, for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis and asthma patients.
The amount of the award was not specified by Pulmatrix; however, the CFFT website says that such awards average $300,000 per year for non-clinical studies.
Pulmatrix CEO Robert Clarke commented, “This award will help fund the non-clinical safety studies needed for the Phase 1/1B clinical trial that we plan to begin in 2018. It underscores the potential for PUR1900 to treat this serious condition, which is currently a major unmet medical need.”
The FDA granted Orphan Drug designation to PUR1900 for the treatment of pulmonary aspergillus infections in cystic fibrosis patients in August 2016 and QIDP status in January 2017.
Read the Pulmatrix press release.
